Glymira 500: Each film coated tablet contains Imeglimin Hydrochloride INN 500 mg
Imeglimin is a first-in-class drug that belongs to a new class of antidiabetic medication known as the "glimins." It is designed to target the key defects of type 2 diabetes mellitus by improving insulin sensitivity in peripheral tissues, enhancing insulin secretion from pancreatic beta cells, and inhibiting hepatic glucose production. Imeglimin works through a unique mechanism involving the mitochondria, which helps to improve the metabolic function and energy balance in patients with type 2 diabetes mellitus.
Imeglimin is indicated for patients with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control.
The usual adult dosage is 500 mg of Imeglimin Hydrochloride administered orally twice daily in the morning and evening.
Hypoglycemia, vomiting, abdominal discomfort, dyspepsia, upper abdominal pain, loose stools, abdominal distension, gastroesophageal reflux disease, urinary bladder infection, diabetic retinopathy, diabetic retinal edema / macular edema, increased blood lactate, increased lipase and weight loss.
Hypoglycemia: This medicine may cause hypoglycemic symptoms. Caution should be maintained while working at heights, drive a car, or operate dangerous machinery.
Renal Impairment Patients: Dosage reduction might be required for patients with renal impairment, eGFR <15 ml/min/1.73 m2
Not recommended.
With medicine: No drug-drug interaction has been reported yet.
With food & others: No interaction.
In the event of an overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring (including obtaining an electrocardiogram), and institute supportive therapy if required.
Do not store above 30 °C. Keep away from light and out of the reach of children.
Glymira 500 tablet: Each box contains 3 blister strips of 10 tablets.